People's Vaccine

Responding to news that the EU has discarded at least 215 million doses of COVID-19 vaccine, Piotr Kolczyński, EU Health Policy Advisor at the People’s Vaccine Alliance and Oxfam, said: “This is further proof that the EU wasted millions of its COVID-19 vaccines, hoarded early in the pandemic, as it locked poorer countries out of access.

As UNGA77 kicks off, Oxfam experts are engaging with a delegation in New York along with remote participation. Oxfam experts will be focused on issues including Hunger and the Global Food System, Climate Justice, the crisis in Yemen, Ukraine, COVID-19 recovery, Inequality, Education, and more. 

Less than half (49 per cent) of the 2.1 billion COVID vaccine donations promised to poorer countries by G7 countries have been delivered, according to new figures published today by Oxfam and the People’s Vaccine Alliance.  

Responding to news that governments at the World Trade Organization (WTO) have agreed a deal on patents for COVID-19 vaccines in developing countries, Max Lawson, Co-Chair of the People’s Vaccine Alliance and Head of Inequality Policy at Oxfam, said: “This is absolutely not the broad intellectual property waiver the world desperately needs to ensure access to vaccines and treatments for everyone, everywhere.

Up to a quarter of a billion people are at risk of falling into extreme poverty this year due to the COVID-19 pandemic, climate crisis and the crisis in Ukraine. Global inequality threatens to rise massively unless more is done to effectively address this situation.
 

In response to the commitments made at President Biden’s Second COVID-19 Summit today, especially the licensing of publicly owned medical technologies, such as the stabilized spike protein for use by the World Health Organization’s (WHO) COVID-19 Technology Access Pool (C-TAP) through the Medicines Patent Pool (MPP), Robbie Silverman, Oxfam America’s Senior Manager of Private Sector Advocacy, made the following statement:

Responding to the WTO’s published ‘outcome’ of negotiations over a waiver of Trade-Related aspects of Intellectual Property (TRIPS), Max Lawson, Head of Inequality Policy for Oxfam and co-chair of the People's Vaccine Alliance, said: "This text is a recognition that WTO rules on intellectual property are a clear barrier to ensuring people get the vaccines, tests, and treatments they need. It is a tragedy that it has taken almost two years and millions of deaths to reach this point and a travesty that the action proposed today falls well short of what is needed."

An Oxfam resolution before Moderna shareholders received 24 percent of the nominal vote or 29 percent of the independent vote factoring in the 17 percent of the vote share owned by the company's directors and senior executives. A similar resolution before Pfizer shareholders garnered 27 percent of the vote.
 

In separate virtual addresses to the shareholders of Moderna, Pfizer, and Johnson & Johnson (JNJ), Oxfam called on the pharmaceutical corporations to improve COVID-19 vaccine equity and access so that everyone, everywhere has access to these life-saving shots. 

In response to reports of a potential compromise agreed by the EU, South Africa, India and the US for a waiver of intellectual property rules for COVID vaccines, Max Lawson, Head of Inequality Policy for Oxfam and co-chair of the People's Vaccine Alliance, said: